Dark

Check out our API

AHI
Advanced Health Intelligence Ltd.
stock NASDAQ

Inactive

Jan 31, 2024

1.50USD-2.547%(-0.04)12,201

Pre-market

0.00USD-100.000%(-1.54)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsTrends

AHI Reddit Mentions

Subreddits

Limit Labels Price

We have sentiment values and mention counts going back to 2017. The complete data set is available via the API.

Take me to the API

AHI Specific Mentions

As of Nov 10, 2025 9:49:53 PM EST (<1 min. ago)

Includes all comments and posts. Mentions per user per ticker capped at one per hour.

12 days ago • u/Anonycullen • r/pennystocks • ixhl_phase_2_data_positive_and_statistically • 𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 :stonk: • B

Incannex (Nasdaq: IXHL) provided a shareholder update on Oct 30, 2025 highlighting Phase 2 successes, capital discipline, and late‑stage planning for 2026. Key clinical results include IHL‑42X showing up to an 83% AHI reduction from baseline with strong patient‑reported outcomes and a favorable safety profile, and PSX‑001 demonstrating statistically significant improvements on HAM‑A and multiple secondary measures with sustained benefit over 11 weeks and no serious adverse events. The company reports no use of its ATM since Aug 28, 2025 and total shares outstanding remain 347,705,507. Incannex plans FDA engagement to define pivotal pathways, maintain operational readiness, and explore partnerships and disciplined capital deployment.
IHL-42X Phase 2: AHI reduction up to 83%
PSX-001 Phase 2: statistically significant HAM-A and multi-measure efficacy
PSX-001: sustained symptom relief over 11 weeks.
https://www.stocktitan.net/news/IXHL/incannex-provides-shareholder-update-highlighting-clinical-progress-6kl73tq94h9j.html

12 days ago • u/Anonycullen • r/pennystocks • ixhl_phase_2_data_positive_and_statistically • 𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 :stonk: • B

Incannex (Nasdaq: IXHL) provided a shareholder update on Oct 30, 2025 highlighting Phase 2 successes, capital discipline, and late‑stage planning for 2026. Key clinical results include IHL‑42X showing up to an 83% AHI reduction from baseline with strong patient‑reported outcomes and a favorable safety profile, and PSX‑001 demonstrating statistically significant improvements on HAM‑A and multiple secondary measures with sustained benefit over 11 weeks and no serious adverse events. The company reports no use of its ATM since Aug 28, 2025 and total shares outstanding remain 347,705,507. Incannex plans FDA engagement to define pivotal pathways, maintain operational readiness, and explore partnerships and disciplined capital deployment.
IHL-42X Phase 2: AHI reduction up to 83%
PSX-001 Phase 2: statistically significant HAM-A and multi-measure efficacy
PSX-001: sustained symptom relief over 11 weeks.
https://www.stocktitan.net/news/IXHL/incannex-provides-shareholder-update-highlighting-clinical-progress-6kl73tq94h9j.html

Share